Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: RC48 + Chemo vs Trastuzumab/Inetetamab + Chemo in HER2+ ABC
NCT07366840Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 3 trial of disitamab vedotin in breast cancer, sponsored by Fudan University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07366840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366840.